Isis Pharmaceuticals hired Richard Brown to head up GeneTrove, its functional genomics division. Brown, who also serves as an Isis VP, will oversee the expected launch of the divisions functional genomics database later this year.
Update from the Trega Biosciences (recently acquired by Lion) fallout front: Tregas chief commercial officer Mark Schwartz wound up on the payroll at Calyx Therapeutics, where hes the new CEO. Marks skills are a perfect match to Calyxs needs, says Somesh Sharma, cofounder of the company. Lets just hope for Schwartzs sake that Calyx isnt a perfect match for Lion.
Amersham partner Molecular Staging announced some scientific acquisitions Michael Egholm, previously with Applied Biosystems, comes on board as veep of research, and Steve Piccoli is the new VP of diagnostics.
Senomyx plays musical chairs, and Lubert Stryer gets to take a break. Paul Grayson was appointed CEO and succeeds Stryer to chairman of the board, while Mark Zoller takes Stryers place as CSO. Saiid Zarrabian, who left Pharmacopeia in December, joins as president and COO. Stryer, who helped found Senomyx, will return to Stanford University.
Arcady Mushegian was hired by the Stowers Institute for Medical Research to be director of bioinformatics. He was previously a senior scientist at ag company Akkadix.
Terry Allread, formerly at ThermoFinnigan, joined automation and instrumentation firm GeneMachines as vice president of manufacturing. Patricia Gray comes to the company as vice president of development.
While Celera and its public-sector counterparts continue to quibble, Human Genome Sciences is getting friendlier with government types. The two latest additions to the companys board of directors are Richard Holbrooke, former US ambassador to the UN, and Richard Danzig, former Secretary of the Navy. Does HGS aspire to world dominance?
Joanne Luciano, who recently vacated her position at 3rd Millennium, celebrated the award of her second patent last month. Luciano plans to develop this and another of her patents methods for predicting the therapeutic outcome of a treatment and automated treatment selection under the auspices of her company Predictive Medicine, which she formed to apply advances in IT, analytical techniques, and biotechnology for the more effective clincial use of prescription medications.